TNNI3K is a cardiac-specific and cardiac troponin I(cT n I)-interacting MAP kinase, known to play important roles in promoting cardiac differentiation, maintenance of beating rhythm and contractual force. The molecula...TNNI3K is a cardiac-specific and cardiac troponin I(cT n I)-interacting MAP kinase, known to play important roles in promoting cardiac differentiation, maintenance of beating rhythm and contractual force. The molecular structure of TNNI3 K contains three kinds of domain: a seven or ten NH2-terminal ankyrin repeat domain followed by a protein kinase domain and a COOH-terminal serine-rich domain. There are many binding sites in the structure of TNNI3 K for binding to ATP, magnesium, nucleotide, protein kinase C, antioxidant protein 1(AOP-1) and cT n I, indicating TNNI3 K has many interacting partners. This review summarizes the evidence, hypothesis and significance of TNNI3 K interacting with TNNI3 and its other putative interaction partners. From the literature, the interaction partners of TNNI3 K are divided into 2 types following their phenotypic pattern of functions, positive interaction(to increase the cardiac performance) or negative interaction(to suppress the cardiac performance). Following their binding sites, it also can be divided into other 2 types: binding to C-terminal domain(e.g., cT n I) or binding to both ankyrin repeat domain and C-terminal domains(AOP-1).To date, a well understood partner of TNNI3 K is cT nI, from the molecular structure, physiological function, mechanisms and its significance in some physiological and pathophysiological conditions. There are many reasons to believe that, with more understanding on the TNNI3 K interacting with its partners, we can understand more roles of TNNI3 K in some cardiac diseases.展开更多
目的对2例限制型心肌病患儿进行高通量测序,明确其可能的致病原因。方法提取患儿及其父母外周血基因组DNA,进行目标基因或全外显子测序并进行生物信息学分析,筛查与心肌病相关致病基因变异,并用Sanger测序法进行位点验证。结果例1存在TN...目的对2例限制型心肌病患儿进行高通量测序,明确其可能的致病原因。方法提取患儿及其父母外周血基因组DNA,进行目标基因或全外显子测序并进行生物信息学分析,筛查与心肌病相关致病基因变异,并用Sanger测序法进行位点验证。结果例1存在TNNI3基因c.549+1G>T杂合变异,父母未检出该变异,为新发变异,且目前未见报道,根据美国医学遗传学与基因组学学会(American College of Medical Genetics and Genomics,ACMG)遗传变异分类标准与指南,判定为致病变异(PVS1+PS2+PM2)。例2和父亲的TNNI3基因存在c.433C>T(p.Arg145Trp)杂合变异,Clinvar、HGMD数据库检索结果显示其为致病变异,根据ACMG标准与指南判定为可能致病变异(PS3+PM1+PP3)。结论TNNI3基因变异可能为2例限制型心肌病患儿的致病原因,基因检测结果为患儿的临床诊断提供了依据。展开更多
Background： Restrictive cardiomyopathy （RCM） is the least common cardiomyopathy in which the walls are rigid and the heart is restricted from stretching and filling properly. Cardiac troponin I （cTnI） mutation-ca...Background： Restrictive cardiomyopathy （RCM） is the least common cardiomyopathy in which the walls are rigid and the heart is restricted from stretching and filling properly. Cardiac troponin I （cTnI） mutation-caused myofibril Ca2＋ hypersensitivity has been shown to be associated with impaired diastolic function. This study aimed to investigate the linkage between the genotype and clinical therapy of RCM. Methods： Five sporadic pediatric RCM patients confirmed by echocardiography were enrolled in this study.Whole-exome sequencing （WES） was performed for the cohort to find out candidate causative gene variants. Sanger sequencing confirmed the WES-identified variants. Results： TNNI3 variants were found in all of the five patients. R192H mutation was shared in four patients while R204H mutation was found only in one patient. Structure investigation showed that the C terminus of TNNI3 was flexible and mutation on the C terminus was possible to cause the RCM. Catechins were prescribed for the five patients once genotype was confirmed. Ventricular diastolic function was improved in three patients during the follow-up. Conclusions： Our data demonstrated that TNNI3 mutation-induced RCM1 is the most common type of pediatric RCM in this study. In addition, WES is a reliable approach to identify likely pathogenic genes of RCM and might be useful for the guidance of clinical treatment scheme.展开更多
文摘TNNI3K is a cardiac-specific and cardiac troponin I(cT n I)-interacting MAP kinase, known to play important roles in promoting cardiac differentiation, maintenance of beating rhythm and contractual force. The molecular structure of TNNI3 K contains three kinds of domain: a seven or ten NH2-terminal ankyrin repeat domain followed by a protein kinase domain and a COOH-terminal serine-rich domain. There are many binding sites in the structure of TNNI3 K for binding to ATP, magnesium, nucleotide, protein kinase C, antioxidant protein 1(AOP-1) and cT n I, indicating TNNI3 K has many interacting partners. This review summarizes the evidence, hypothesis and significance of TNNI3 K interacting with TNNI3 and its other putative interaction partners. From the literature, the interaction partners of TNNI3 K are divided into 2 types following their phenotypic pattern of functions, positive interaction(to increase the cardiac performance) or negative interaction(to suppress the cardiac performance). Following their binding sites, it also can be divided into other 2 types: binding to C-terminal domain(e.g., cT n I) or binding to both ankyrin repeat domain and C-terminal domains(AOP-1).To date, a well understood partner of TNNI3 K is cT nI, from the molecular structure, physiological function, mechanisms and its significance in some physiological and pathophysiological conditions. There are many reasons to believe that, with more understanding on the TNNI3 K interacting with its partners, we can understand more roles of TNNI3 K in some cardiac diseases.
文摘目的对2例限制型心肌病患儿进行高通量测序,明确其可能的致病原因。方法提取患儿及其父母外周血基因组DNA,进行目标基因或全外显子测序并进行生物信息学分析,筛查与心肌病相关致病基因变异,并用Sanger测序法进行位点验证。结果例1存在TNNI3基因c.549+1G>T杂合变异,父母未检出该变异,为新发变异,且目前未见报道,根据美国医学遗传学与基因组学学会(American College of Medical Genetics and Genomics,ACMG)遗传变异分类标准与指南,判定为致病变异(PVS1+PS2+PM2)。例2和父亲的TNNI3基因存在c.433C>T(p.Arg145Trp)杂合变异,Clinvar、HGMD数据库检索结果显示其为致病变异,根据ACMG标准与指南判定为可能致病变异(PS3+PM1+PP3)。结论TNNI3基因变异可能为2例限制型心肌病患儿的致病原因,基因检测结果为患儿的临床诊断提供了依据。
文摘Background： Restrictive cardiomyopathy （RCM） is the least common cardiomyopathy in which the walls are rigid and the heart is restricted from stretching and filling properly. Cardiac troponin I （cTnI） mutation-caused myofibril Ca2＋ hypersensitivity has been shown to be associated with impaired diastolic function. This study aimed to investigate the linkage between the genotype and clinical therapy of RCM. Methods： Five sporadic pediatric RCM patients confirmed by echocardiography were enrolled in this study.Whole-exome sequencing （WES） was performed for the cohort to find out candidate causative gene variants. Sanger sequencing confirmed the WES-identified variants. Results： TNNI3 variants were found in all of the five patients. R192H mutation was shared in four patients while R204H mutation was found only in one patient. Structure investigation showed that the C terminus of TNNI3 was flexible and mutation on the C terminus was possible to cause the RCM. Catechins were prescribed for the five patients once genotype was confirmed. Ventricular diastolic function was improved in three patients during the follow-up. Conclusions： Our data demonstrated that TNNI3 mutation-induced RCM1 is the most common type of pediatric RCM in this study. In addition, WES is a reliable approach to identify likely pathogenic genes of RCM and might be useful for the guidance of clinical treatment scheme.
